Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
56,025,691
-
Share change
-
+1,787,576
-
Total reported value
-
$774,315,063
-
Put/Call ratio
-
85%
-
Price per share
-
$13.82
-
Number of holders
-
156
-
Value change
-
+$10,576,060
-
Number of buys
-
69
-
Number of sells
-
73
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2022
As of 30 Jun 2022,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
156 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,025,691 shares.
The largest 10 holders included
JPMORGAN CHASE & CO, BlackRock Inc., Capital World Investors, Palo Alto Investors LP, VANGUARD GROUP INC, Polar Capital Holdings Plc, FRANKLIN RESOURCES INC, STATE STREET CORP, JENNISON ASSOCIATES LLC, and BAMCO INC /NY/.
This page lists
156
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.